SIMCERE PHARMAC. GRP LTD Asset Resilience Ratio
SIMCERE PHARMAC. GRP LTD asset resilience ratio. SIMCERE PHARMAC. GRP LTD (S2P) has an Asset Resilience Ratio of 0.44% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SIMCERE PHARMAC. GRP LTD (S2P) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of SIMCERE PHARMAC. GRP LTD (2021–2025)
Asset resilience ratio of SIMCERE PHARMAC. GRP LTD from 2021 to 2025. This chart shows how SIMCERE PHARMAC. GRP LTD's Asset Resilience Ratio has changed over time. Read S2P liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SIMCERE PHARMAC. GRP LTD's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SIMCERE PHARMAC. GRP LTD assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €65.53 Million | 0.44% |
| Total Liquid Assets | €65.53 Million | 0.44% |
Asset Resilience Insights
- Limited Liquidity: SIMCERE PHARMAC. GRP LTD maintains only 0.44% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SIMCERE PHARMAC. GRP LTD Industry Peers by Asset Resilience Ratio
Compare SIMCERE PHARMAC. GRP LTD's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Cansino Biologics Inc
SHG:688185 |
Drug Manufacturers - Specialty & Generic | 19.62% |
SIMCERE PHARMAC. GRP LTD Asset Resilience Ratio by Year (2021–2025)
SIMCERE PHARMAC. GRP LTD asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for SIMCERE PHARMAC. GRP LTD.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.44% | €65.53 Million ≈ $76.61 Million |
€14.73 Billion ≈ $17.22 Billion |
+0.36pp |
| 2024-12-31 | 0.09% | €10.00 Million ≈ $11.69 Million |
€11.51 Billion ≈ $13.46 Billion |
-0.02pp |
| 2023-12-31 | 0.10% | €11.14 Million ≈ $13.02 Million |
€10.85 Billion ≈ $12.69 Billion |
-8.83pp |
| 2022-12-31 | 8.94% | €964.23 Million ≈ $1.13 Billion |
€10.79 Billion ≈ $12.61 Billion |
-2.97pp |
| 2021-12-31 | 11.91% | €1.21 Billion ≈ $1.41 Billion |
€10.16 Billion ≈ $11.88 Billion |
-- |
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its princi… Read more